King's College London

Research portal

GPCR targets in type 2 diabetes

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Original languageEnglish
Title of host publicationGPCRs
Subtitle of host publicationStructure, Function, and Drug Discovery
PublisherElsevier
Pages367-391
Number of pages25
ISBN (Electronic)9780128162286
DOIs
Published1 Jan 2019

King's Authors

Abstract

Approximately 400 million people worldwide currently have type 2 diabetes (T2D), in which peripheral cells show reduced sensitivity to insulin and islet β-cells do not secrete sufficient insulin to maintain low blood glucose levels. There are a range of therapies in current clinical use to treat T2D, but surprisingly few are GPCR ligands. This chapter reviews the current GPCR-based therapies for T2D, and provides information on potential future candidates that have arisen through GPCR research in insulin-secreting β-cells or insulin target tissues, and on GPCR ligands that are undergoing clinical trials. We also provide a future perspective on GPCR-based T2D therapeutic approaches, emphasizing the importance of refining and discovering new ways to treat T2D to improve the quality of life of individuals with diabetes.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454